in SSC, but in lunate bone in RA pts. According to the MCP joints, the highest synovitis score was found on the second finger in SSC and RA, highest erosion score also on the second finger in SSC, but on the third finger in RA. The highest bone oedema score was found on the third finger in SSC, and also on the third and fifth finger in RA pts.

**Conclusion:** MR inflammatory lesions in SSC are less frequent compared to that in RA but still in significant percentage, confirming the need for early detection and aggressive treatment of both, RA and SSC patients with joint involvement.

**References:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2020-eular.5001

**AB1131**

**STATISTICAL PROCESS CONTROL AND PROCESS MAPPING QUANTIFY THE EFFECTS OF HISTORICAL CHANGES TO THE CONNECTIVE TISSUE DISEASE TESTING ALGORITHM AND IDENTIFY AREAS FOR FUTURE IMPROVEMENT IN A LARGE DIAGNOSTIC IMMUNOLOGY SERVICE**

M. Stevens1, N. Proudlove2, J. Ball3, C. Scott1. 1Barts Health NHS Trust, Immunology Laboratory, London, United Kingdom; 2Alliance Manchester Business School, Manchester, United Kingdom

**Background:** Pathology test turnaround times (TATs) are a limiting factor in patient flow through rheumatology services. Quality improvement (QI) methodologies such as Lean use tools including statistical process control (SPC) and process mapping to study the performance of the whole of a clinical pipeline, expose unnecessary complexity (non-value-adding activity), and streamline processes and staff roles.

**Objectives:** Understand effects of changes made to CTD testing algorithm over last 12 years by measuring some of the effects on TATs. Model current processes and suggest changes to workflow to improve TAT.

**Methods:** High-level flow diagrams of the current testing algorithm, and low-level process maps of analyser and staff processes were drawn. Activity and TATs (working days between report and booking date) for ANA, ENA, DNA and CCP tests were plotted as Xmr control charts.

**Results:** Finding 1: Largest referral laboratory does not currently operate a separate DNA monitoring workflow, resulting in unnecessary ANA and ENA testing (figure 1).

**Finding 2:** Samples are handed off between 3 different lab benches, each of which may be staffed by a different staff member on a different day, and results processing involves handoff to a further 2 different staff members.

**Finding 3:** ANA demand is close to capacity, ENA demand exceeds current capacity (table 1).

**Table 1. Demand for ANA, ENA and DNA tests, compared to capacity**

<table>
<thead>
<tr>
<th>Test</th>
<th>Median Demand (tests/day)</th>
<th>Approx. Capacity (tests/day)</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANA</td>
<td>74</td>
<td>100</td>
<td>Close to 80% recommended by the ILGs</td>
</tr>
<tr>
<td>ENA</td>
<td>38</td>
<td>36</td>
<td>’Less capacity than demand!!’</td>
</tr>
<tr>
<td>DNA</td>
<td>34</td>
<td>100</td>
<td>Plenty</td>
</tr>
</tbody>
</table>

**Finding 4:** Stopping screening DNA requests on ANA result increased the number of DNA tests performed by about 10 samples per day (30%), but decreased turnaround time by a similar proportion (3.3 to 2.3 days, figure 2). It also reduced turnaround times of ANA and ENA tests.

**Conclusion:** Typically for a QI project, the initially simple CTD testing pipeline has accumulated many changes made without consideration of whole system performance, and is now a struggle to run. Improvement ideas to be explored from this work include:

- Liaising with main referral lab to develop a DNA monitoring workflow to reduce unnecessary ANA and ENA testing
- Reduce handoffs, sample journey around lab analysers, and staff hands-on time by:
  - changing ANA test methodology to same as DNA
  - creating new staff roles (analyser operators to perform validation/authorisation steps)
  - Create more capacity for ENA testing by increasing the frequency of this test on the weekly rota
- Create more capacity for service expansion by running analysers at weekends (staff consultation required)
- Reduce demand on service by engaging and educating requestors
- Improve TAT for DNA by:
  - processing samples the day they are booked in, instead of 1 day later
  - auto-validating runs
  - …using control charts to measure improvement

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2020-eular.438

**AB1132**

**EFFECTIVENESS AND SAFETY OF ULTRASOUND-GUIDED FASCIA HYDRORELEASE ON METATARSALGIA WITHOUT SONOGRAPHIC EVIDENCE OF INFLAMMATION IN PATIENTS WITH RHEUMATOID ARTHRITIS.**

M. Suda1,2, K. Muranaka3, S. Ohde4, M. Minoda1. 1Suwa Central Hospital, Rheumatology, Chino, Japan; 2St Luke's International Hospital, Immuno-Rheumatology Center, Chuo City, Japan; 3Suwa Central Hospital, Rheumatology, Chino, Japan; 4St Luke's International University, Graduate School of Public Health, Tokyo, Japan

**Background:** Patients with rheumatoid arthritis (RA) who have metatarsal-palangeal (MTP) joint involvement sometimes complain metatarsalgia without active sonographic inflammation1. Treatment of non-inflammatory metatarsalgia in RA is challenging and the pain sometimes lasts for years even though systemic inflammation completely resolves. On the other hand, intervention to fascia has increasingly attracted attention as a management of non-inflammatory pain2. Recently, we have invented a new technique called ultrason-guided fascia hydrorelease (UGFHR), which injects fluid into “stacking fascia” (defined as high echoic and thickened fascia, often adhering to adjacent structures), making it unglued and instantaneously improving fascial pain.

**Objectives:** This study is aimed for prospective evaluation of effectiveness and safety of UGFHR on metatarsalgia in patients with RA.

**Methods:** We enrolled consecutive 11 patients with RA who came to rheumatology service in Suwa Central Hospital and satisfied the following inclusion and exclusion criteria:

- Inclusion criteria were having at least one MTP joint pain on which the patient has tenderness on the extensor side.
- Exclusion criteria:
  - Systemic inflammation
  - Active sonographic inflammation
  - Active synovitis
  - Active erosion
  - Active bone oedema
  - Active joint effusion
  - active arthritis

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2020-eular.438

**Figure 1. Current testing strategy (left) and suggested improvement (right)**

**Figure 2. Control chart of average TAT of dsDNA antibodies by request date**

**Figure 3. Current testing strategy (left) and suggested improvement (right)**